Skip to content

PRESS RELEASES


PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Integra LifeSciences Announces the Passing of Dr. Richard Caruso, Founder and Former Chairman and CEO
PRINCETON, N.J., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that Dr. Richard Caruso, founder and former chairman and CEO of Integra LifeSciences passed away over the past weekend. “Dr.
View HTML
Toggle Summary Integra LifeSciences Reports Second Quarter 2022 Financial Results
PRINCETON, N.J., July 27, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (NASDAQ: IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2022. Second Quarter 2022 Highlights Second quarter revenues of $398
View HTML
Toggle Summary Integra LifeSciences Appoints Renee Lo as Director
PRINCETON, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (Nasdaq: IART), a leading global medical technology company, today announced the appointment of Renee Lo to its board of directors as an independent director to fill an existing vacancy, effective July 18,
View HTML
Toggle Summary Integra LifeSciences to Host Second Quarter 2022 Financial Results Conference Call on July 27, 2022
PRINCETON, N.J., July 01, 2022 (GLOBE NEWSWIRE) -- ) Integra LifeSciences Holdings Corporation  (NASDAQ: IART), a leading global medical technology company, will release second quarter 2022 financial results on Wednesday, July 27, 2022, prior to the market open. In conjunction with the earnings
View HTML
Toggle Summary Integra LifeSciences Reports First Quarter 2022 Financial Results
PRINCETON, N.J., April 27, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (NASDAQ: IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2022. First Quarter 2022 Highlights Revenues of $376.6 million
View HTML
Toggle Summary Integra LifeSciences to Host First Quarter 2022 Financial Results Conference Call on April 27, 2022
PRINCETON, N.J., April 01, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation  (NASDAQ: IART), a leading global medical technology company, will release first quarter 2022 financial results on Wednesday, April 27, 2022, prior to the market open. In conjunction with the earnings
View HTML
Toggle Summary Integra LifeSciences Launches NeuraGen® 3D Nerve Guide Matrix
The Next Generation of Nerve Conduits PRINCETON, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Corporation (Nasdaq: IART), a leading global medical technology company and pioneers in nerve repair, today announced the launch of NeuraGen ® 3D Nerve Guide Matrix , a resorbable
View HTML
Toggle Summary Integra LifeSciences Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides 2022 Financial Guidance
PRINCETON, N.J., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART) today reported financial results for the fourth quarter and full year ended December 31, 2021, consistent with its preliminary revenue results announced on January 11, 2022.
View HTML
Toggle Summary Integra LifeSciences Reports Preliminary Fourth Quarter and Full-Year 2021 Revenue and Plans $125 Million Share Repurchase
Fourth quarter 2021 revenue is expected to be in a range of $404 million to $406 million, representing an increase of approximately 4% on a reported basis and an increase of approximately 8% on an organic basis compared to the prior year. Full-year 2021 revenue is expected to be in a range of
View HTML
Toggle Summary Integra LifeSciences Reports Third Quarter 2021 Financial Results
Third Quarter 2021 Highlights Revenues of $386.9 million increased 4.5% on a reported basis and 6.7% on an organic basis compared to the prior year; GAAP earnings per diluted share of $0.51, compared to $0.38 in the third quarter of 2020; adjusted earnings per diluted share of $0.86, compared to
View HTML
Toggle Summary Integra LifeSciences Announces Jan De Witte as President and Chief Executive Officer
30-year healthcare and technology veteran with extensive global executive experience and diverse expertise in R&D, commercialization, product management, digital innovation and operations PRINCETON, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a
View HTML
Toggle Summary Integra LifeSciences to Host Third Quarter 2021 Financial Results Conference Call on November 2, 2021
PRINCETON, N.J., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release third quarter 2021 financial results on Tuesday, November 2, 2021, prior to the market open.
View HTML
Toggle Summary Integra LifeSciences Announces Participation in Upcoming Investor Conferences
PRINCETON, N.J., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today that it is participating in the following investor conferences: On September 9, 2021, Carrie Anderson, executive vice president
View HTML
Toggle Summary Integra LifeSciences Reports Second Quarter 2021 Financial Results
Raises Full-Year 2021 Guidance Second Quarter 2021 Highlights Revenues of $390.0 million increased 50.8% on a reported basis and 48.7% on an organic basis compared to the prior year; GAAP earnings per diluted share of $0.41, compared to $(0.00) in the second quarter of 2020; adjusted earnings per
View HTML
Toggle Summary Integra LifeSciences Announces Positive Clinical Outcomes for PriMatrix® Dermal Repair Scaffold for the Management of Diabetic Foot Ulcers
Data Shows a Single Application of PriMatrix Closed More Wounds Than Standard of Care Alone PRINCETON, N.J., July 19, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Corporation (Nasdaq: IART), a leading global medical technology company, today announced positive clinical outcomes for
View HTML